26 results
SC TO-T/A
EX-99
KNTE
Kinnate Biopharma Inc
19 Mar 24
Third party tender offer statement (amended)
4:44pm
, which is designed for cancers with FGFR2 and FGFR3 alterations. Kinnate also has early-stage programs, including a c-MET inhibitor that targets resistant
SC TO-T/A
EX-99
KNTE
Kinnate Biopharma Inc
19 Mar 24
Third party tender offer statement (amended)
4:44pm
, an investigational pan-RAF inhibitor which targets cancers with BRAF and NRAS-driven alterations, was one of Kinnate’s lead product candidates. Kinnate’s other lead … early-stage programs, including a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4 selective program. For more information
SC TO-T
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Third party tender offer statement
5:24pm
inhibitor that targets resistant variants and a brain penetrant CDK4 selective program.
Kinnate was incorporated under the laws of the State of Delaware
SC14D9C
EX-99.1
KNTE
Kinnate Biopharma Inc
1 Mar 24
Written communication relating to third party tender offer
8:53am
which targets cancers with BRAF and NRAS-driven alterations, was one of the Company’s lead product candidates. The Company’s other lead product candidate … programs, including a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4 selective program. For more information, visit
8-K
EX-99.1
KNTE
Kinnate Biopharma Inc
1 Mar 24
Entry into a Material Definitive Agreement
8:50am
which targets cancers with BRAF and NRAS-driven alterations, was one of the Company’s lead product candidates. The Company’s other lead product candidate … programs, including a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4 selective program. For more information, visit
SC TO-C
EX-99.1
yzq6g ltp9gtbzz
27 Feb 24
Information about tender offer
4:42pm
SC14D9C
EX-99.1
x3qtj1tvhhlgds3fzq
21 Feb 24
Written communication relating to third party tender offer
6:01am
8-K
EX-99.1
ndghy78zzc
16 Feb 24
Entry into a Material Definitive Agreement
9:10am
8-K
EX-99.1
v29th2x6t
9 Nov 23
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
4:14pm
8-K
EX-99.1
qcwlojamuxneqemcsgg
18 Sep 23
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
4:28pm
8-K
EX-99.1
21b ivpgxnv07qi
8 Aug 23
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
4:16pm
8-K
EX-99.1
bkfexksk2 ypj8h
10 Nov 22
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
4:26pm
8-K
EX-99.1
stzf 76335u05g7s
28 Mar 22
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
4:11pm
8-K
EX-99.1
kmg21mxyqn lidx55t
6 Jan 22
Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones
4:13pm
8-K
EX-99.1
tur9ir3
10 Nov 21
Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results
4:16pm
10-K
9rih73lau06f0
29 Mar 21
Annual report
4:26pm
424B4
cgw6mehcqit6zz
3 Dec 20
Prospectus supplement with pricing info
4:48pm
S-1/A
q1ytica 33
30 Nov 20
IPO registration (amended)
6:05am